Article in Journal of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
7 citing papers in PubMed, 5 citations in OpenAlex.
Werner J D Ouwendijk *HerpesLabNL, Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands.ORCID 0000-0001-8393-296X
Pavitra Roychoudhury *Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Anthony L CunninghamCentre for Virus Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
Keith R JeromeDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
David M KoelleDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Paul R KinchingtonDepartment of Ophthalmology and of Molecular Microbiology and Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-1901-9970
Ian MohrDepartment of Microbiology, New York University School of Medicine, New York, New York, USA.
Angus C WilsonDepartment of Microbiology, New York University School of Medicine, New York, New York, USA.
Georges G M G M Verjans *HerpesLabNL, Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-2465-2674
Daniel P Depledge *Department of Microbiology, New York University School of Medicine, New York, New York, USA.ORCID 0000-0002-4292-0599
University of Washington · USErasmus University Rotterdam · NLNew York University · USMedizinische Hochschule Hannover · DEThe University of Sydney · AUUniversity of Pittsburgh · US
Funding
Virus Production and Manipulation of Protein/Gene Expression ModuleP30EY008098 · NEI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Paul R. Kinchington · 1989 to 2026
$17.8M
Control of Translation in Herpesvirus Infected Cells - Resubmission - 1R01GM056927 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Ian J Mohr · 1999 to 2026
$7.6M
Large Scale T Cell Epitope Discovery: Local and Systemic T cell Response to Herpes Simplex Virus75N93019C00063 · NIAID · UNIVERSITY OF WASHINGTON · PI MYER, TIM · 2019 to 2023
$5.5M
Virus Host Interactions that Regulate Translation in Cells Infected with HSV-1R01AI073898 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MOHR, IAN J · 2008 to 2020
$5.0M
Cutaneous Pathogen-Specific Tissue Resident Memory T Cells in Human AgingR01AG064800 · NIA · UNIVERSITY OF WASHINGTON · PI KOELLE, DAVID M · 2019 to 2023
$3.5M
Role of VZV Latency Transcript (VLT) and ORF63 in latency and reactivationR01AI151290 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KINCHINGTON, PAUL R., VERJANS, GEORGES MICHEL · 2021 to 2025
$3.5M
VZV vaccine attenuation and the DNA damage responseR01AI158510 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Paul R. Kinchington · 2022 to 2026
$3.2M
EPITRANSCRIPTOMIC REGULATION OF CYTOMEGALOVIRUS INFECTIONR01AI152543 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DEPLEDGE, DANIEL PEARCE, MOHR, IAN J · 2020 to 2025
$2.7M
Endonuclease-mediated disruption of latent HSV as curative therapyR01AI132599 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI JEROME, KEITH R · 2018 to 2022
$2.6M
Interplay between nuclear stress responses and herpesvirus latencyR01AI176335 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Ian J Mohr, ANGUS C WILSON · 2024 to 2026
$2.0M
High-Performance Compute Cluster for Comprehensive Cancer and Infectious Diseases ResearchS10OD028685 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2020 to 2020
$2.0M
Viral disruption of host transcriptome integrityR01AI170583 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ANGUS C WILSON · 2023 to 2026
Most individuals are latently infected with herpes simplex virus type 1 (HSV-1), and it is well-established that HSV-1 establishes latency in sensory neurons of peripheral ganglia. However, it was recently proposed that latent HSV-1 is also present in immune cells recovered from the ganglia of experimentally infected mice. Here, we reanalyzed the single-cell RNA sequencing (scRNA-Seq) data that formed the basis for that conclusion. Unexpectedly, off-target priming in 3' scRNA-Seq experiments enabled the detection of non-polyadenylated HSV-1
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Reanalysis of single-cell RNA sequencing data does not support herpes simplex virus 1 latency in non-neuronal ganglionic cells in mice. · full record | OpenQuestion